| HMDB0001856 | Protocatechuic acid | 99-50-3 |  | C7H6O4 | 154.121
154.026608673 | Not Available |
| HMDB0001866 | 3,4-Dihydroxymandelic acid | 775-01-9 |  | C8H8O5 | 184.1461
184.037173366 | Not Available |
| HMDB0002708 | Cyanidin | 13306-05-3 |  | C15H11O6 | 287.2442
287.055563084 | Not Available |
| HMDB0003173 | Petunidin | 13270-60-5 |  | C16H13O7 | 317.2702
317.06612777 | Not Available |
| HMDB0003501 | cis-Caffeic acid | 4361-87-9 |  | C9H8O4 | 180.1574
180.042258744 | Not Available |
| HMDB0004063 | Metanephrine | 5001-33-2 |  | C10H15NO3 | 197.231
197.105193351 | Not Available |
| HMDB0004215 | 3,3',4'5-Tetrahydroxystilbene | 10083-24-6 |  | C14H12O4 | 244.246
244.073558866 | Not Available |
| HMDB0005794 | Quercetin | 117-39-5 |  | C15H10O7 | 302.2357
302.042652674 | Not Available |
| HMDB0005800 | Luteolin | 491-70-3 |  | C15H10O6 | 286.2363
286.047738052 | Not Available |
| HMDB0011754 | Methyldopa | 555-30-6 |  | C10H13NO4 | 211.2145
211.084457909 | Not Available |
| HMDB0012226 | Entacapone | 130929-57-6 |  | C14H15N3O5 | 305.286
305.101170605 | Not Available |
| HMDB0014400 | Diethylstilbestrol | 56-53-1 |  | C18H20O2 | 268.3502
268.146329884 | - Engel LL, Weidenfield J, Merriam GR: Metabolism of diethylstilbestrol by rat liver: a preliminary report. J Toxicol Environ Health Suppl. 1976;1:37-44. [PubMed:11352 ]
|
| HMDB0014468 | Tolcapone | 134308-13-7 |  | C14H11NO5 | 273.2408
273.063722467 | - Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
- Ries V, Selzer R, Eichhorn T, Oertel WH, Eggert K: Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study. Clin Neuropharmacol. 2010 May;33(3):142-50. doi: 10.1097/WNF.0b013e3181d99d6f. [PubMed:20502133 ]
- Guay DR: Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease. Pharmacotherapy. 1999 Jan;19(1):6-20. [PubMed:9917075 ]
- Keating GM, Lyseng-Williamson KA: Tolcapone: a review of its use in the management of Parkinson's disease. CNS Drugs. 2005;19(2):165-84. [PubMed:15697329 ]
- Truong DD: Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease. Clin Interv Aging. 2009;4:109-13. Epub 2009 May 14. [PubMed:19503773 ]
- Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R, Alce G, Iudicello JE, Akbar N, Egan MF, Goldberg TE, Weinberger DR: Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology. 2007 May;32(5):1011-20. Epub 2006 Oct 25. [PubMed:17063156 ]
- Stocchi F, De Pandis MF: Utility of tolcapone in fluctuating Parkinson's disease. Clin Interv Aging. 2006;1(4):317-25. [PubMed:18046910 ]
- Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Jarvinen T, Mannisto PT: Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther. 2003 Feb;304(2):498-506. [PubMed:12538800 ]
- Tai CH, Wu RM: Catechol-O-methyltransferase and Parkinson's disease. Acta Med Okayama. 2002 Feb;56(1):1-6. [PubMed:11873938 ]
- Kaakkola S: Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs. 2000 Jun;59(6):1233-50. [PubMed:10882160 ]
- Ruottinen HM, Rinne UK: COMT inhibition in the treatment of Parkinson's disease. J Neurol. 1998 Nov;245(11 Suppl 3):P25-34. [PubMed:9808337 ]
|
| HMDB0014979 | Dobutamine | 34368-04-2 |  | C18H23NO3 | 301.3801
301.167793607 | - Raxworthy MJ, Youde IR, Gulliver PA: Catechol-O-methyltransferase: substrate-specificity and stereoselectivity for beta-adrenoceptor agents. Xenobiotica. 1986 Jan;16(1):47-52. [PubMed:2868577 ]
- Yan M, Webster LT Jr, Blumer JL: Kinetic interactions of dopamine and dobutamine with human catechol-O-methyltransferase and monoamine oxidase in vitro. J Pharmacol Exp Ther. 2002 Apr;301(1):315-21. [PubMed:11907189 ]
|
| HMDB0015272 | Micafungin | 235114-32-6 |  | C56H71N9O23S | 1270.274
1269.438350313 | - Groll AH, Stergiopoulou T, Roilides E, Walsh TJ: Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Investig Drugs. 2005 Apr;14(4):489-509. [PubMed:15882123 ]
- Wiederhold NP, Lewis JS 2nd: The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother. 2007 Jun;8(8):1155-66. [PubMed:17516879 ]
|
| HMDB0029185 | 5-(3',4'-Dihydroxyphenyl)-gamma-valerolactone | 191666-22-5 |  | C11H12O4 | 208.213
208.073558866 | Not Available |
| HMDB0029233 | 3,4-Dihydroxyphenylvaleric acid | |  | C11H14O4 | 210.2265
210.089208936 | Not Available |
| HMDB0029251 | Pinotin A aglycone | |  | C25H19O9 | 463.413
463.102907206 | Not Available |
| HMDB0029478 | Meloside L | 55196-48-0 |  | C27H30O16 | 610.5175
610.153384912 | Not Available |
| HMDB0030235 | eq-4''-Hydroxymaysin | 170079-82-0 |  | C27H30O14 | 578.5187
578.163555668 | Not Available |
| HMDB0030502 | (2S,4S,6S)-2-[2-(4-Hydroxy-3-meyhoxyphenyl)ethyl]tetrahydro-6-(4,5-dihydroxy-3-methoxyphenyl)-2H-pyran-4-ol | 182227-93-6 |  | C21H26O7 | 390.4269
390.167853186 | Not Available |
| HMDB0030541 | 3,3',4',7-Tetrahydroxyflavan | |  | C15H14O5 | 274.2687
274.084123558 | Not Available |
| HMDB0030559 | m-Trigallic acid | 2131-66-0 |  | C21H14O13 | 474.3281
474.043440534 | Not Available |
| HMDB0030569 | Swertiajaponin | 6980-25-2 |  | C22H22O11 | 462.4035
462.116211546 | Not Available |
| HMDB0030609 | Xanthochymuside | 31654-49-6 |  | C36H32O16 | 720.6297
720.169034976 | Not Available |
